Drug overdose remains one of Victoria’s most under-discussed causes of preventable death. Most deaths involve prescription medicines, often combined with alcohol or other depressants. Our newsroom has looked at the data, the harm-reduction tools that work, and the policy debates currently active in Victoria.
Overdose is preventable. The mix of pharmacotherapy, take-home naloxone, supervised consumption, syringe exchange and pill-testing represents the practical evidence base — and Victoria has moved on most of these fronts in the last decade, with one prominent exception still being debated.
What the data tells us
The Penington Institute publishes Australia’s most consulted overdose data set, the Annual Overdose Report, which draws on the National Coronial Information System. Year on year, the report has shown unintentional drug-induced deaths in Australia running at over 2,000, with Victoria among the larger contributors in absolute numbers. The single most consistent finding — and the one that most challenges public assumptions — is that pharmaceutical opioids and benzodiazepines are involved in more deaths than heroin or stimulants. Polydrug toxicity is the rule, not the exception.
The Coroners Court of Victoria publishes its own analysis through the Coroners Prevention Unit, which has produced influential reports on prescription-medicine deaths and on regional overdose patterns. Both data sources point in the same direction: overdose is largely a problem of legal medicines used in unsafe combinations, not a problem confined to street drugs.
Pharmacotherapy programs
Opioid pharmacotherapy — methadone and buprenorphine, including the long-acting depot formulations — is the cornerstone of opioid-use disorder treatment. Victoria’s program is delivered through community pharmacies, GPs accredited as prescribers, and specialist alcohol and other drug services. The evidence base for pharmacotherapy in reducing fatal overdose is among the strongest in addiction medicine.
Access has improved with the listing of long-acting buprenorphine on the Pharmaceutical Benefits Scheme and with prescriber expansion programs that have reduced waitlists. Gaps remain — particularly in regional Victoria, where prescriber numbers are thin and pharmacy participation is uneven. Tom Whitford has reported on rural towns where the nearest dosing pharmacy is an hour’s drive each way.
Take-home naloxone
Naloxone reverses opioid overdose. It binds to the same receptors as opioids but displaces them, restoring breathing within minutes. Until recently, naloxone was prescription-only in most circumstances. The national Take Home Naloxone Program made naloxone — including the nasal spray (Nyxoid) and the prefilled injection (Prenoxad) — available for free without a prescription through participating pharmacies and AOD services.
Naloxone is now PBS-listed under the program. People who use opioids, their families, peer workers and many frontline services carry it. It is safe to administer to someone you suspect of opioid overdose: if you are wrong about the cause, naloxone does not harm them. If you are right, it can save their life until ambulance arrives. Calling 000 is always the first step — naloxone is a bridge, not a substitute for emergency care.
The supervised injecting room at North Richmond
The Medically Supervised Injecting Room at North Richmond opened on a trial basis in 2018 in response to a cluster of overdose deaths in surrounding streets. The service operates inside the North Richmond Community Health centre and is staffed by nurses and addiction specialists. Clients use pre-obtained substances under supervision, reducing fatal-overdose risk and connecting people to treatment, housing and primary care.
An independent evaluation found the room had managed thousands of overdoses without a fatality on site and was associated with a reduction in publicly discarded injecting equipment in the surrounding precinct. It also found unresolved community impacts in the immediate vicinity, particularly around the school next door.
The future of the service has been politically contested. The state government’s announcement in 2023 that it would not proceed with a second supervised injecting room in the Melbourne CBD was controversial, with public-health bodies arguing the evidence supported expansion and community groups in the city centre raising concerns about siting. The North Richmond service continues to operate at the time of writing, with its statutory framework extended.
Pill-testing pilots
Pill testing, also known as drug-checking, lets people who intend to use illicit drugs have their substance analysed before consumption. Services typically test for the presence of high-risk adulterants and for the substance’s identity, then deliver a brief intervention from a clinician. The evidence from international services — particularly the long-running programs in Switzerland, the Netherlands and Portugal — is that drug-checking changes consumption decisions and reduces the harms most associated with adulterated supply.
Australia’s first state-sanctioned festival pill-testing service operated in the ACT, with a fixed-site service following. Victoria announced in late 2024 that it would establish drug-checking services as part of its harm-reduction response, with pilots running through the 2024-25 summer festival season and a fixed-site service to follow. The pilot is being evaluated by an academic consortium. Early reporting from the festival pilots is consistent with the international literature: presence-detection of high-potency adulterants prompted disposal in a meaningful share of cases.
Needle and syringe programs
Needle and syringe programs are one of the most evaluated public-health interventions in Australia. They reduce blood-borne virus transmission, connect people to health services, and do not increase drug use. Victoria has a network of fixed and outreach services, often co-located with primary health and AOD providers. Cohealth, the Salvation Army, Harm Reduction Victoria and Star Health are among the major providers in metropolitan Melbourne, with regional programs delivered through local community health and hospital networks.
The pharmacy syringe access program complements the dedicated services, providing low-cost or subsidised equipment through participating pharmacies — a particular asset in regional towns without a fixed needle and syringe program site.
What works and what is missing
The evidence base, summarised:
- Works: Pharmacotherapy, naloxone distribution, supervised consumption services, drug-checking, needle and syringe programs, peer-led education, real-time prescription monitoring (SafeScript in Victoria).
- Promising: Heroin-assisted treatment for entrenched dependence (operating overseas, not yet in Australia), expanded depot buprenorphine access, Hospital in the Reach style outreach for people leaving custody.
- Missing or under-resourced: Residential rehabilitation beds, particularly in regional Victoria; dual-diagnosis services that handle co-occurring mental illness and substance use; post-release transition support for people exiting prison, who face very high overdose risk in the first weeks after release.
Talking about overdose
Stigma is a barrier to help-seeking. The Mindframe guidelines for reporting on alcohol and other drugs ask media to avoid sensationalised language, to reference help-seeking pathways, and to treat substance dependence as a health issue, not a moral failure. Our newsroom follows those principles. We do not name people who have died of overdose unless families have spoken publicly. We do not detail substances or doses in ways that could constitute a how-to. We treat overdose as the public-health emergency it is, and we point readers to the supports that can keep them and the people they care about alive.
Where to get help
If someone is unconscious or not breathing normally, call 000 immediately. DirectLine (1800 888 236) is Victoria’s 24/7 alcohol and drug counselling service. Family Drug Help (1300 660 068) supports families and friends. Take-home naloxone is available free at participating pharmacies and AOD services — find a provider via health.gov.au. The Penington Institute publishes practical overdose-prevention resources at penington.org.au. For broader support, Lifeline is 13 11 14, 13YARN (13 92 76) provides culturally safe support, and Beyond Blue is 1300 22 4636.
